Simplify Logo

Full-Time

Histotechnologist

Confirmed live in the last 24 hours

Natera

Natera

1,001-5,000 employees

Biotechnology firm specializing in genetic testing

Hardware
Biotechnology
Healthcare

Compensation Overview

$72.3k - $90.4kAnnually

Entry, Junior

Austin, TX, USA

Category
Diagnostics & Laboratory Professionals
Medical, Clinical & Veterinary
Required Skills
Communications
Requirements
  • Associates degree and completion of a certified clinical program in medical laboratory sciences in histopathology or equivalent.
  • ASCP certified HT/HTL
  • Excellent written and oral communication skills.
  • Able to accurately understand and convey information to team members.
  • Detail-oriented. Ability to think broadly about the importance of information.
  • Ability to work independently.
Responsibilities
  • Preparation of tissues and stained slides of a high quality
  • Troubleshooting of technical problems related to sample preparation
  • Participation and compliance with state and federal regulations
  • Provide professional support for Clinical Trial team by means of accurate data collection, organization, and transfer
  • Performs other duties as assigned

Natera focuses on genetic testing and diagnostics, providing advanced solutions for cancer patients, transplant patients, and individuals assessing hereditary health risks. Their main technology, cell-free DNA (cfDNA) testing, analyzes DNA fragments in the blood to detect minimal traces of cancer and assess organ health. Natera stands out by offering specialized tests like the Signatera ctDNA test and Panorama NIPT, along with genetic counseling services. The company's goal is to improve patient care through accurate genetic insights and early detection of health issues.

Company Stage

IPO

Total Funding

$1.2B

Headquarters

Austin, Texas

Founded

2004

Growth & Insights
Headcount

6 month growth

8%

1 year growth

20%

2 year growth

52%
Simplify Jobs

Simplify's Take

What believers are saying

  • Natera's continuous innovation, such as the launch of the Prospera Heart test with DQS, demonstrates its commitment to improving patient outcomes and maintaining market leadership.
  • The company's diverse product offerings across oncology, transplant health, and women's health provide multiple revenue streams and reduce dependency on a single market.
  • Significant investments from entities like Massachusetts Financial Services Co. MA indicate strong financial backing and confidence in Natera's growth potential.

What critics are saying

  • Allegations of deceptive sales and billing practices could damage Natera's reputation and lead to legal and financial repercussions.
  • The highly competitive nature of the genetic testing market requires constant innovation and differentiation to maintain market share.

What makes Natera unique

  • Natera's focus on cell-free DNA (cfDNA) technology for a wide range of applications, from oncology to prenatal screening, sets it apart from competitors who may specialize in only one area.
  • The introduction of unique features like the Donor Quantity Score (DQS) for transplant rejection detection enhances the accuracy and reliability of their tests, distinguishing them from other genetic testing companies.
  • Natera's extensive portfolio of over 200 peer-reviewed publications underscores its commitment to scientific validation and credibility, which is a significant competitive advantage.

Benefits

Flexible medical plans

Investment options

Time off

Workplace perks